Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-cash Items (2021 - 2024)

Historic Non-cash Items for Inhibikase Therapeutics (IKT) over the last 3 years, with Q4 2024 value amounting to $31.1 million.

  • Inhibikase Therapeutics' Non-cash Items changed N/A to $31.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $31.1 million, marking a year-over-year change of. This contributed to the annual value of $31.1 million for FY2024, which is N/A changed from last year.
  • As of Q4 2024, Inhibikase Therapeutics' Non-cash Items stood at $31.1 million.
  • In the past 5 years, Inhibikase Therapeutics' Non-cash Items registered a high of $31.1 million during Q4 2024, and its lowest value of $300000.0 during Q4 2022.
  • In the last 3 years, Inhibikase Therapeutics' Non-cash Items had a median value of $2.0 million in 2021 and averaged $11.1 million.
  • The largest annual percentage gain for Inhibikase Therapeutics' Non-cash Items in the last 5 years was 8500.0% (2022), contrasted with its biggest fall of 8500.0% (2022).
  • Over the past 3 years, Inhibikase Therapeutics' Non-cash Items (Quarter) stood at $2.0 million in 2021, then tumbled by 85.0% to $300000.0 in 2022, then soared by 10266.67% to $31.1 million in 2024.
  • Its Non-cash Items was $31.1 million in Q4 2024, compared to $300000.0 in Q4 2022 and $2.0 million in Q4 2021.